Health and Fitness Health and Fitness
Mon, May 10, 2010

Aoxing Pharmaceutical Company Announces May Investor Conferences Participation


Published on 2010-05-10 05:40:15 - Market Wire
  Print publication without navigation


NEW YORK, NY--(Marketwire - May 10, 2010) - Aoxing Pharmaceutical Company, Inc. (NYSE Amex: [ AXN ]) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced the Company's participation in the following conferences.

  • Rodman & Renshaw Annual Global Investment Conference 2010, to be held from May 16-18, 2010 at the Grosvenor House Hotel, London, United Kingdom. Management present at 9:50 am at local time on May 17 and meet with institutional investors throughout May 17.

  • Oppenheimer 4th Annual China Dragon Call Conference, to be held from May 18-20, 2010 at Oppenheimer's 300 Madison Avenue Offices in New York City. Management present at 3:30 pm EDT on May 19 and meet institutional investors throughout March 19 and 20.

  • Due to management time constraints, the Company cancelled its pre-scheduled presentation at Deutsche Bank Access Asia Conference 2010 in Singapore from May 10 to May 13, 2010.

For further details, please contact your institutional sales representative.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its main operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has a strategic alliance partnership with QRxPharma and American Oriental Bioengineering, Inc. For more information: [ www.aoxingpharma.com ].

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contributing Sources